

## Our Vision

To be the Global Leader in Testing for Life


## Our Mission

To contribute to a safer and healthier world by providing our customers with innovative and high-quality laboratory, research and advisory services whilst creating opportunities for our employees and generating sustainable shareholder value

## Our Values

Customer Focus, Quality, Competence & Team Spirit and Integrity

## Revenues in €million



## Eurofins overview

Eurofins is Testing for Life. The Eurofins network of companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agrosience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

## History

Eurofins Scientific was founded in 1987 with 3 employees and 1 laboratory to market a patented analytical method used to verify the origin and purity of several types of food and beverages and identify sophisticated fraud not detectable by other methods.

Today, the Eurofins Group is a leading provider of testing and analytical services with:

- an international network of more than **950 laboratories** in **59 countries**;
- over **65,000** staff;
- a portfolio of over **200,000** analytical methods;
- more than **450 million** tests performed each year.

## A commitment to innovation and sustainability

Since its foundation, Eurofins has contributed significantly to the advancement of science. We are proud of the discoveries our specialists have made in a broad range of sectors, from food to pharma or forensics testing. Our laboratories around the world are helping to improve cancer treatments, catch criminals, safeguard the health of bees, ensure our food and water is safe, indicate paternity, protect transplant patients' lives and combat viruses. Whether we are helping to improve health outcomes, ensure food safety or determine environmental impact, sustainability is at the heart of our work. To serve this purpose, Eurofins Sustainability Solutions brings together a wide range of Eurofins companies' market-leading sustainability offerings and solutions in one place, to enable corporations, organisations and governments to contribute to product and enterprise sustainability. On the ground, we are working to reduce our carbon footprint through sustainable business practices. In 2025, Eurofins' absolute carbon emissions declined by 7% vs 2024. In terms of carbon intensity relative to revenues, we are now 44% below the 2019 level. Lastly, the Eurofins Foundation supports charities and NGOs across the world, who share our goal of making the world a safer and healthier place for all.

## Recent developments

Eurofins, through its activities, continues to make meaningful contributions to Testing for Life. Eurofins Medical Device Services North America's GMP PFAS testing and screening solution is the first developed and commercialized for the medical device industry. It provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributing to medical device and patient safety. Eurofins Sustainability Services' Origin ID™, a leading cotton origin verification service, provides information about the origin of cotton in products and promotes supply chain transparency across the apparel, home textiles, and personal hygiene industries. Cotton traceability has become a requirement in many regions – making origin verification through testing a necessity to check compliance against traceability regulations. Eurofins Food & Feed Testing offers a test for the detection of the emetic *Bacillus cereus* toxin, cereulide, a particularly heat-stable, pH-resistant and enzyme-tolerant toxin found in a variety of food products such as dairy, infant formula and oil. Eurofins' state-of-the-art LC-MS/MS analysis, performed in accordance with ISO standard 18465:2017, supports milk and baby food manufacturers in their compliance efforts and helps safeguard public health.

## Financial and stock market performance

2025 marked 28 years since Eurofins' IPO on the Paris stock exchange on the 24<sup>th</sup> October 1997. On September 17<sup>th</sup>, 2021, Eurofins joined the CAC 40 index and has been, for almost three decades, one of the fastest growing listed European companies. Since its IPO, Eurofins' revenues have increased by 31% each year (in compound average) to reach €7.3 billion in 2025. Furthermore, in the 28 years since its IPO to December 31<sup>st</sup> 2025, Eurofins has delivered a remarkable total shareholder return (reflecting both share price appreciation and reinvestment of dividends) of around 38,300%, equivalent to a compounded annual growth rate (CAGR) of over 23%. Among all companies with listings in major European exchanges over the 1997-2022 period analysed by a research firm, Eurofins ranked highest in terms of total shareholder return.

Eurofins was pleased to have delivered against our 2025 objectives, with a 24% EPS growth, accelerating organic revenue growth, margin expansion, and higher free cash flow. 2025 demonstrated the significant underlying operating leverage of the Eurofins network, even when organic growth was below secular averages.

## Outlook

As Eurofins moves through 2026 and 2027, the benefits of our hub-and-spoke network and maturing start-up investments should continue to accumulate, and towards the end of the period, the completion of projects to fully digitalise the laboratory network will enable further productivity gains including material savings in IT costs. Going forward, through our research, innovation and efficiency Eurofins intends to accelerate our contributions to improving Testing for Life, and to a healthier and safer world.

## Eurofins shares are listed on Euronext Paris

(since IPO at €0.1829 on 24 October 1997)

### Tickers

ISIN FR0014000MR3, Euronext ERF, Reuters EUFI.PA, Bloomberg ERF FP

### Index Membership

Euronext Paris: CAC 40, EURONEXT 100, SBF 120, SBF TOP 80 EW, CAC ALL-SHARE, CAC ALL-TRADABLE, CAC HEALTH CARE, CAC LARGE 60.

Euronext Amsterdam: EN EUROPE 500, EN EUROZONE 300.

Other: MSCI Europe, STOXX Europe 600, STOXX Global Industry Neutral ESG 600

## Contact and Addresses

Investor Relations

[ir@sc.eurofinseu.com](mailto:ir@sc.eurofinseu.com)

Tel +32 2 766 1620

Avenue Herrmann-Debroux 48

B-1160 Brussels, Belgium

Please refer to our [on-line group directory](#) for laboratory contact information